Trial Profile
To adjuvant chemotherapy after curative treatment of head and neck cancer A study of alternate-day administration definitive TS-1
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2015
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 31 Jan 2013 New trial record